The pharmacogenetic analyses requested from the patients before Coumadin treatment are available in our Center.

CYP2C9 and VKORC1 region are examined in the patients. The patients with determined mutations in these genetic region can be protected from the side effects depending to the medicine and may cause death by changing their treatment protocols.